<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601510</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000581134</org_study_id>
    <secondary_id>KRDI-TUM-STI571</secondary_id>
    <secondary_id>KRDI-TUM-GLIVEC-CSTI571BDE54</secondary_id>
    <secondary_id>EU-20797</secondary_id>
    <secondary_id>NOVARTIS-KRDI-TUM-STI571</secondary_id>
    <secondary_id>EUDRACT-2006-005792-17</secondary_id>
    <nct_id>NCT00601510</nct_id>
  </id_info>
  <brief_title>Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer</brief_title>
  <official_title>A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Drugs used in chemotherapy, such as capecitabine and cisplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving imatinib together with combination chemotherapy may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of imatinib when given&#xD;
      together with capecitabine and cisplatin in treating patients with unresectable or metastatic&#xD;
      stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerable dose and assess the safety and tolerability of&#xD;
           imatinib mesylate in combination with capecitabine and cisplatin in patients with&#xD;
           unresectable or metastatic gastric cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the preliminary antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  To assess the response with regard to the expression and/or mutation of the tyrosine&#xD;
           kinase receptors PDGF-R and c-kit in gastric cancer.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of imatinib mesylate.&#xD;
&#xD;
      Patients receive oral imatinib mesylate once daily on days -4 to 21 in course 1 and on days&#xD;
      1-21 in all subsequent courses, oral capecitabine twice daily on days 1-14, and cisplatin IV&#xD;
      on day 1. Courses repeat every 3 weeks* for 12 months in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *First course is 25 days.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall tumor response as assessed by RECIST</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression of disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Imatinib mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Imatinib mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <arm_group_label>Imatinib mesylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed gastric cancer&#xD;
&#xD;
               -  Unresectable and/or metastatic disease&#xD;
&#xD;
          -  Incurable with any conventional multimodality approach by interdisciplinary assessment&#xD;
             of the local tumor board&#xD;
&#xD;
          -  Immunohistochemical documentation of c-kit (CD117) and PDGF-R overexpression by tumor&#xD;
             if obtainable (preferably on a tumor sample taken within 6 weeks of study entry)&#xD;
&#xD;
          -  At least one evaluable site of disease according to RECIST criteria&#xD;
&#xD;
          -  No known brain metastasis or CNS disorder that might alter study compliance or may&#xD;
             worsen during or following therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC ≥ 3,000/μL&#xD;
&#xD;
          -  ANC ≥ 2,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 2.5 times ULN (5 times ULN if hepatic metastases present)&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for up to 3&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  No known or documented hypersensitivity against fluoropyrimidines, tyrosine kinase&#xD;
             inhibitors, cisplatin, other platinums, or their respective derivatives&#xD;
&#xD;
          -  No gastrointestinal disorder that might affect the gastrointestinal absorption of&#xD;
             capecitabine or imatinib mesylate or ability to swallow for the oral administration of&#xD;
             capecitabine or imatinib mesylate&#xD;
&#xD;
          -  At least 5 years since prior primary malignancy except if the other primary malignancy&#xD;
             is not currently clinically significant nor requiring active intervention, or if other&#xD;
             primary malignancy is a basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other concurrent malignant disease&#xD;
&#xD;
          -  No NYHA class III-IV cardiac disease (i.e., congestive heart failure or myocardial&#xD;
             infarction within the past 6 months)&#xD;
&#xD;
          -  No severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic&#xD;
             renal disease, or active uncontrolled infection)&#xD;
&#xD;
          -  No known neuropathy, impaired hearing, history of seizures, and/or psychiatric&#xD;
             disorder that might alter study compliance or may worsen during or following therapy&#xD;
&#xD;
          -  No documented dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)&#xD;
&#xD;
          -  No known diagnosis of HIV infection or other serious uncontrolled infections&#xD;
&#xD;
          -  No significant history of non-compliance to medical regimens or inability to grant&#xD;
             reliable informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No chemotherapy or investigational agents within the past 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) unless the disease is rapidly progressing&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  No major surgery within the past 2 weeks&#xD;
&#xD;
          -  No concurrent warfarin or acetaminophen&#xD;
&#xD;
               -  Therapeutic anticoagulation using heparin or low-molecular weight heparin allowed&#xD;
&#xD;
          -  No concurrent sorivudine or related substances&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy and biologic agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Ebert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

